Precigen, Inc. (PGEN) Bundle
A Brief History of Precigen, Inc. (PGEN)
Founding and Early Years
Founding and Early Years
Precigen, Inc., formerly known as Intrexon Corporation, was founded in 1998 by Randal J. Kirk. The company aimed to leverage synthetic biology to develop innovative therapies and products across various sectors.
Corporate Transition
In 2019, Intrexon rebranded itself to become Precigen, Inc. This change reflected a strategic pivot towards its core focus on developing advanced therapies in the fields of immunotherapy and gene editing.
Initial Public Offering and Financial Data
Precigen went public on the NASDAQ stock exchange under the ticker symbol PGEN. The company's IPO in 2013 valued the company at approximately $1.5 billion at its peak.
Recent Financial Performance
As of Q2 2023, Precigen reported total revenue of $16.9 million for the quarter, with net loss amounting to $18.1 million. The company had total assets valued at $211.7 million.
| Year | Total Revenue ($ millions) | Net Loss ($ millions) | Total Assets ($ millions) |
|---|---|---|---|
| 2020 | 38.4 | (60.4) | 208.5 |
| 2021 | 44.2 | (73.6) | 194.2 |
| 2022 | 52.3 | (85.0) | 180.0 |
| 2023 (Q2) | 16.9 | (18.1) | 211.7 |
Research and Development Focus
Precigen focuses on multiple therapeutic areas including oncology and infectious diseases, prominently featuring its UltraCAR-T technology aimed at improving T-cell therapies.
Collaborations and Partnerships
In 2021, Precigen entered into a partnership with Novartis to develop gene therapies using its proprietary platform. This collaboration is expected to enhance the development of transformative therapies in gene editing.
Market Position and Competitors
As of 2023, Precigen competes with several companies in the synthetic biology and gene therapy sectors including CRISPR Therapeutics, Intellia Therapeutics, and Bluebird Bio.
Stock Performance
As of October 2023, Precigen's stock traded at approximately $2.56 per share, reflecting a market capitalization of about $437 million.
Future Outlook
Analysts forecast that Precigen could experience significant growth, projecting revenues to potentially reach $100 million by 2025, contingent upon successful clinical trials and product launches.
A Who Owns Precigen, Inc. (PGEN)
Company Overview
Precigen, Inc. (NASDAQ: PGEN) is a biotechnology company focused on the development of transformative gene and cell therapies. The company, headquartered in Germantown, Maryland, aims to harness the potential of its proprietary technologies to treat disease and improve the lives of patients.
Major Shareholders
As of the latest filing in September 2023, the following large institutional investors hold significant shares in Precigen, Inc.
| Shareholder | Ownership Percentage | Number of Shares Held |
|---|---|---|
| BlackRock, Inc. | 12.1% | 9,236,000 |
| The Vanguard Group, Inc. | 11.5% | 8,677,000 |
| Wellington Management Company, LLP | 8.7% | 6,550,000 |
| State Street Corporation | 6.3% | 4,731,000 |
| Geode Capital Management, LLC | 4.9% | 3,700,000 |
Executive Management
The executive management team plays a critical role in the company’s direction and strategy. Key executives include:
- Helen Sabzevari, Ph.D. - President and CEO
- Charles W. (Chuck) Dyer - Chief Financial Officer
- Mark McClain - Chief Operating Officer
- Richard W. (Rick) Heller - Chief Scientific Officer
Recent Financial Performance
For the second quarter of 2023, Precigen reported the following financial metrics:
| Financial Metric | Q2 2023 | Q2 2022 |
|---|---|---|
| Revenue | $5.2 million | $4.9 million |
| Net Loss | ($14.1 million) | ($12.5 million) |
| Total Assets | $85 million | $70 million |
| Total Liabilities | $45 million | $40 million |
| Cash and Cash Equivalents | $30 million | $25 million |
Insider Ownership
Insider ownership provides insight into the alignment between management and shareholders. As of the latest update:
| Insider | Position | Ownership Percentage |
|---|---|---|
| Helen Sabzevari, Ph.D. | President and CEO | 2.3% |
| Charles W. Dyer | Chief Financial Officer | 1.1% |
| Mark McClain | Chief Operating Officer | 0.8% |
| Board Members | N/A | 3.5% |
Stock Performance
Precigen's stock price performance over the past year has showcased volatility:
| Date | Closing Price | Market Capitalization |
|---|---|---|
| September 1, 2023 | $3.25 | $486 million |
| June 1, 2023 | $2.80 | $420 million |
| March 1, 2023 | $4.10 | $615 million |
| December 1, 2022 | $5.00 | $750 million |
Recent Developments
Recent announcements from Precigen include:
- September 2023: Initiation of the Phase 2 trial for PRGN-3005.
- August 2023: Partnership with a major pharmaceutical company for co-development of next-generation therapies.
- July 2023: Reported positive interim results from the Phase 1 trial for PRGN-2012.
Precigen, Inc. (PGEN) Mission Statement
Company Overview
Precigen, Inc. (PGEN) is a biotechnology company focusing on the development of transformative therapies. The company's mission is to harness the power of its proprietary technology platforms to create advanced cellular therapies and gene editing solutions.
Mission Statement
The mission statement of Precigen is to “unlock the potential of complex biology to deliver the next generation of transformative medicines.” This reflects the company's commitment to innovation and improvement in treatment modalities.
Core Values
- Integrity
- Innovation
- Collaboration
- Accountability
- Excellence
Financial Overview
Precigen reported a total revenue of $30.1 million for the fiscal year 2022, marking an increase from $20.0 million in 2021.
The company maintains a market capitalization of approximately $175 million as of October 2023.
Research and Development Investment
In 2022, Precigen allocated $46.3 million towards research and development, reflecting a strategic focus on enhancing its technology and therapeutic offerings.
Partnerships and Collaborations
Precigen has established several partnerships aimed at advancing its therapeutic candidates. Key partnerships include:
| Partner | Collaboration Focus | Year Established |
|---|---|---|
| Caribou Biosciences | Gene Editing | 2021 |
| Intellia Therapeutics | CRISPR Technologies | 2022 |
| OGT | Genomics | 2023 |
Therapeutic Areas of Focus
- Oncology
- Autoimmunity
- Infectious Diseases
Recent Developments
In Q3 2023, Precigen announced advancements in its PRGN-3005 clinical trial, designed for the treatment of HPV-associated cancers. The preliminary results demonstrated a 73% rate of tumor regression in treated patients.
Stock Performance
As of October 2023, Precigen's stock (PGEN) has shown a year-to-date increase of 45%, reflecting positive investor sentiment and company growth prospects.
Employee Count
Precigen employs approximately 200 individuals, focusing on a workforce that emphasizes research, development, and commercial activities.
Future Outlook
Looking ahead, Precigen aims to expand its pipeline, with ongoing clinical trials and potential entry into new indications. The company projects an increase in collaboration revenue by approximately 15% year-on-year through 2025.
How Precigen, Inc. (PGEN) Works
Business Model and Focus Areas
Business Model and Focus Areas
Precigen, Inc. operates in the biotechnology sector focusing on gene therapy, immuno-oncology, and biologics manufacturing. Its primary aim is to develop advanced therapies for cancer and rare diseases.
Key Technologies
The company utilizes several proprietary platforms:
- Precigen ActoBio: This platform focuses on the development of gene therapies using smart, regulated protein expression.
- UltraPorator: A technology designed for gene delivery into cells.
- PRGN-3005: This is its lead product candidate, aimed at treating solid tumors using a novel approach to immunotherapy.
Financial Overview
As of Q3 2023, Precigen reported the following financial metrics:
| Metric | Q3 2023 Amount (in millions) |
|---|---|
| Revenue | $12.4 |
| Net Loss | ($18.9) |
| Cash and Cash Equivalents | $148.7 |
| Total Assets | $292.1 |
| Total Liabilities | $221.5 |
Research and Development Pipeline
Precigen is investing significantly in its R&D programs. The pipeline includes:
- PRGN-2012: An investigational gene therapy for HPV-associated malignancies.
- PRGN-3007: Designed for the treatment of advanced cancers.
- Prigen-A: A gene therapy focused on rare diseases.
Partnerships and Collaborations
Precigen has formed strategic alliances to enhance its research potential:
- Collaboration with University of Pennsylvania: Focusing on developing CAR T-cell therapies.
- Partnership with Intrexon: For gene editing technologies.
Market Performance
As of late October 2023, Precigen's stock (PGEN) performance reflects:
| Date | Closing Price | Market Capitalization (in millions) |
|---|---|---|
| October 27, 2023 | $2.30 | $359.2 |
| October 20, 2023 | $2.45 | $375.6 |
| October 13, 2023 | $2.28 | $355.5 |
Investment Considerations
Investors consider the following regarding Precigen:
- Growth Potential: Significant opportunities in gene therapy and immuno-oncology.
- Risks: High R&D costs and regulatory hurdles.
- Funding: Recent offerings raised approximately $50 million in 2023.
How Precigen, Inc. (PGEN) Makes Money
Revenue Streams
Revenue Streams
Precigen, Inc. (PGEN) generates revenue primarily through the following channels:
- Therapeutic product sales
- Research and development collaborations
- Licensing agreements
- Grant funding
Therapeutic Product Sales
Precigen's therapeutic product sales include the commercialization and development of its clinical-stage therapies.
As of Q3 2023, Precigen reported $1.5 million in revenue from product sales.
Research and Development Collaborations
Research collaborations with other biotech and pharmaceutical companies are a significant revenue source. In 2022, they formed collaborations that generated approximately $10 million.
As of October 2023, ongoing collaborations are expected to yield potential funding of around $25 million over several years.
Licensing Agreements
Licensing agreements involve agreements with other companies to use Precigen's technology and intellectual property.
In 2022, Precigen signed licensing agreements valued at $5.2 million.
In 2023, the anticipated revenue from licensing is projected to be $7 million.
Grant Funding
Grant funding from various governmental and non-governmental organizations contributes to revenue. In 2022, Precigen received approximately $3 million in grants.
For 2023, the forecast for grant funding is expected to be around $4 million.
Financial Performance Overview
| Year | Total Revenue | Product Sales | Collaborative Revenue | Licensing Revenue | Grant Revenue |
|---|---|---|---|---|---|
| 2020 | $7.1 million | $0.5 million | $3 million | $2 million | $1.6 million |
| 2021 | $15.3 million | $1.2 million | $5 million | $7 million | $2.1 million |
| 2022 | $23.8 million | $1.8 million | $10 million | $5.2 million | $3 million |
| 2023 (est.) | $33.5 million | $1.5 million | $25 million | $7 million | $4 million |
Market Analysis
Precigen operates in the field of gene therapy and immunotherapy.
The global gene therapy market was valued at approximately $3.89 billion in 2021 and is projected to reach $11.88 billion by 2026.
Clinical Development Projects
Precigen is engaged in multiple clinical trials, including:
- PRGN-3006 for hematologic malignancies
- PRGN-2012 for HPV-associated malignancies
- PRGN-4001 for immune-oncology
Investment and Market Capitalization
As of Q3 2023, Precigen's market capitalization is approximately $390 million.
The company had total assets of $341 million and total liabilities of $163 million as of Q2 2023.
Precigen, Inc. (PGEN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support